Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors

被引：0
|
作者：
Manceron, C. [1 ]
Colard-Thomas, J. [2 ]
Maria, A. T. J. [3 ]
Duflos, C. [4 ]
Herman, F. [4 ]
Simon, M. [5 ]
Viala, M. [2 ]
Faillie, J. L. [6 ]
Palassin, P. [1 ]
机构：
[1] CHU Montpellier, Dept Med Pharmacol & Toxicol, Montpellier, France
[2] Montpellier Canc Inst, Dept Med Oncol, Montpellier, France
[3] Montpellier Univ Hosp, Inst Regenerat Med & Biotherapy IRMB, St Eloi Hosp, Internal Med Immuno Oncol MEDI2O, Montpellier, France
[4] Univ Montpellier, Dept Med Informat, CHU Montpellier, Montpellier, France
[5] CHU Montpellier, Clin Oncol Pharm Unit UPCO, Montpellier, France
[6] Univ Montpellier, Dept Med Pharmacol & Toxicol, IDESP INSERM, CHU Montpellier, Montpellier, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2023年 / 37卷
关键词：
dosing schedule; extended interval dosing; Immune Checkpoint Inhibitors; immune-related adverse events; standard interval dosing;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PM1-001
引用
收藏
页码：48 / 48
页数：1
相关论文
共 50 条
  • [1] Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study
    Colard-Thomas, J.
    Manceron, C.
    Duflos, C.
    Herman, F.
    Simon, M.
    Maria, A. T. J.
    Faillie, J. -L.
    Viala, M.
    Palassin, P.
    [J]. ESMO OPEN, 2023, 8 (06)
  • [2] Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study
    Cantini, Luca
    Paoloni, Francesco
    Pecci, Federica
    Spagnolo, Francesco
    Genova, Carlo
    Tanda, Enrica Teresa
    Aerts, Sophie
    Rebuzzi, Sara Elena
    Fornarini, Giuseppe
    Zoratto, Federica
    Fancelli, Sara
    Lupi, Alessio
    Della Corte, Carminia Maria
    Parisi, Alessandro
    Bennati, Chiara
    Ortega, Cinzia
    Atzori, Francesco
    Piovano, Pier Luigi
    Orciuolo, Corrado
    De Tursi, Michele
    Ghidini, Michele
    Botticelli, Andrea
    Scagnoli, Simone
    Belluomini, Lorenzo
    Leporati, Rita
    Veccia, Antonello
    Di Giacomo, Anna Maria
    Festino, Lucia
    Cortinovis, Diego
    Acquati, Mirko
    Filetti, Marco
    Giusti, Raffaele
    Tucci, Marco
    Sergi, Maria Chiara
    Garutti, Mattia
    Puglisi, Fabio
    Manglaviti, Sara
    Citarella, Fabrizio
    Santoni, Matteo
    Rijavec, Erika
    Lo Russo, Giuseppe
    Santini, Daniele
    Addeo, Alfredo
    Antonuzzo, Lorenzo
    Indini, Alice
    Rocchi, Marco Bruno Luigi
    Cortellini, Alessio
    Grossi, Francesco
    Ascierto, Paolo Antonio
    Aerts, Joachim G. J. V.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (07) : 796 - 804
  • [3] Safety of Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors for Advanced NSCLC
    Pierre, Clemence
    Goter, Thomas
    Lena, Herve
    Le Guen, Yannick
    Ricordel, Charles
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (02) : E14 - E16
  • [4] Extended interval dosing in patients with cancer receiving immune checkpoint inhibitors: Safety analysis from the EDICI study
    Cantini, Luca
    Paoloni, Francesco
    Pecci, Federica
    Spagnolo, Francesco
    Aerts, Sophie
    Indini, Alice
    Fancelli, Sara
    Citarella, Fabrizio
    Garutti, Mattia
    Sergi, Maria Chiara
    Giusti, Raffaele
    Di Giacomo, Anna Maria
    Veccia, Antonello
    Cortinovis, Diego Luigi
    Leporati, Rita
    Scaglione, Ilaria Mariangela
    Atzori, Francesco
    Festino, Lucia
    Aerts, Joachim
    Berardi, Rossana
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Evaluation of immune related adverse events following extended interval dosing of immune checkpoint inhibitors
    Deviley, Jake Anthony
    Hayashi-Tanner, Yacki
    Frankki, Susan M.
    Marinier, David E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Immune checkpoint inhibitors and risk of immune-mediated adverse events: a cohort study comparing extended versus standard interval administration
    Lessard-Roy, Amelia
    Marchand, Roxanne
    Lemieux, Pierre
    Masse, Melanie
    Lacerte, Alexandre
    Carmichael, Pierre-Hugues
    Laurin, Danielle
    [J]. CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [7] Immune checkpoint inhibitors and risk of immune-mediated adverse events: a cohort study comparing extended versus standard interval administration
    Amélia Lessard-Roy
    Roxanne Marchand
    Pierre Lemieux
    Mélanie Masse
    Alexandre Lacerte
    Pierre-Hugues Carmichael
    Danielle Laurin
    [J]. Clinical and Experimental Medicine, 24
  • [8] Natalizumab: extended versus standard interval dosing in the real world
    Wagner, B.
    Richter, S.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 880 - 881
  • [9] Safety of extended interval dosing of Natalizumab in clinical practice
    Pastor, S.
    Fernandez-Fournier, M.
    Sastre Real, M.
    Perez Lucas, J.
    Puertas Munoz, I.
    Tallon, A.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 335 - 336
  • [10] Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study
    Mukherjee, Sarbajit
    Ibrahimi, Sami
    Machiorlatti, Michael
    Roman, Darwin
    Saleem, Rabia
    Hassan, Ayesha
    Baxley, Allison
    Vesely, Sara
    Aljumaily, Raid
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2018, 25 (06) : E767 - E768
12345